Evaluation of hypertension as a marker of bevacizumab efficacy

Journal of Gastrointestinal Cancer

Volumn 40, Issue 3-4, 2009, Pages 101-108

  Ryanne Wu, Rebekah ^a   Lindenberg, Peter A ^b   Slack, Rebecca ^c   Noone, Anne Michelle ^c   Marshall, John L ^c   He, Aiwu R ^c  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

Bevacizumab; Colorectal cancer; Hypertension

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 73549124774     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-009-9104-9     Document Type: Article

References (24)

1. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
2. CS Fuchs J Marshall E Mitchell, et al. 2007 Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study J Clin Oncol 25 4779 4786 10.1200/JCO.2007.11.3357 1:CAS:528:DC%2BD2sXhtlCgsLbM 17947725 (Pubitemid 350086481)
3. HS Hochester LL Hart K Ramanathan, et al. 2008 Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study J Clin Oncol 26 3523 3529 10.1200/JCO.2007.15.4138
4. LB Saltz S Clarke E Diaz-Rubio, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D 18421054
5. F Kabbinavar HI Hurwitz L Fehrenbacher, et al. 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 10.1200/JCO.2003.10.066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D 12506171
6. BJ Giantonio PJ Catalano N Meropol, et al. 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 10.1200/JCO.2006.09.6305 1:CAS:528:DC%2BD2sXlsVyntbc%3D 17442997 (Pubitemid 46733080)
7. WL Ince AM Jubb SN Holden, et al. 2005 Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab J Natl Cancer Inst 97 981 989 1:CAS:528:DC%2BD2MXlvF2hsL8%3D 15998951
8. AM Jubb HI Hurwitz W Bai, et al. 2006 Impact of vascular endothelial growth factor-a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer J Clin Oncol 24 217 227 10.1200/JCO.2005.01.5388 1:CAS:528:DC%2BD28XhtVKqtr8%3D 16365183 (Pubitemid 46622051)
9. X Zhu S Wu WL Dahut CR Parikh 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 186 193 10.1053/j.ajkd.2006.11.039 1:CAS:528:DC%2BD2sXis1Kgu78%3D 17261421 (Pubitemid 46178407)
10. HTD Annex McKendall GR BH, et al. 2003 The viva trial: vascular endothelial growth factor in ischemia for vascular angiogenesis Circulation 107 1359 1365 10.1161/01.CIR.0000061911.47710.8A 12642354 (Pubitemid 36350732)
11. T Shih C Lindley 2006 Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Ther 28 1779 1803 10.1016/j.clinthera.2006. 11.015 1:CAS:528:DC%2BD2sXhtVClsbg%3D 17212999 (Pubitemid 46038527)
12. ML Veronese KT Flaherty R Townsend, et al. 2004 Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: mechanisms of hypertension J Clin Oncol 14 22 Suppl 2035
13. JR Horowitz A Rivard R van der Zee, et al. 1997 Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension Arterioscler Thromb Vasc Biol 17 2793 2800 1:CAS:528: DyaK1cXisV2jtg%3D%3D 9409257
14. JD Hood CJ Meininger M Ziche HJ Grander 1998 VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol Heart Circ Physiol 274 H1054 H58 1:CAS:528:DyaK1cXitVSjs7c%3D
15. JJ Mourad G des Guetz H Debbabi BI Levy 2008 Blood pressure rise following angiogenesis inhibition by bevacizumab: a crucial role of microcirculation Ann Oncol 19 927 934 10.1093/annonc/mdm550 18056916 (Pubitemid 351627309)
16. M Scartozzi E Galizia S Chiorrini, et al. 2009 Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 227 230 10.1093/annonc/mdn637 1:STN:280:DC%2BD1M7jtlWltg%3D%3D 18842611
17. P Bono H Elfving T Utriainen, et al. 2009 Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Ann Oncol 20 393 394 10.1093/annonc/mdn729 1:STN:280:DC%2BD1M7jsFOrsA%3D%3D 19211503
18. C Kohne E Bajetta E Lin, et al. 2007 Final results of CONFIRM 2: A multinational, randomized, double-blinded phase III study in 2nd line patients with metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 or placebo J Clin Oncol 18 25 Suppl 4033
19. KD Miller LI Chap F Holmes, et al. 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 10.1200/JCO.2005.05.098 1:CAS:528:DC%2BD2MXitVKitrk%3D 15681523 (Pubitemid 46224178)
20. BJ Giantonio PJ Catalano NJ Meropol, et al. 2005 High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 16 23 Suppl 2
21. JR Hecht T Trarbach E Jaeger, et al. 2005 A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) J Clin Oncol 16 23 Suppl 3
22. M Kozloff J Hainsworth S Badarinath, et al. 2006 Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRite) J Clin Oncol 18 24 Suppl 3537
23. S Berry D Cunningham M Michael, et al. 2006 Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and Capecitabine for metastatic colorectal cancer-first B E A trial J Clin Oncol 18 24 Suppl 3534
24. SW Agero AL Dusza C Benvenuto-Adrade KJ Busam P Myskowski AC Halpern 2006 Dermatologic side effects associated with the epidermal growth factor receptor inhibitors J Amer Acad Dermatol 55 657 670 10.1016/j.jaad.2005.10.010 (Pubitemid 44436627)